The Effects of Daridorexant on Patients With Comorbid Insomnia Disorder and Untreated Mild Obstructive Sleep Apnoea: A Post Hoc Subgroup Analysis of a Phase 3, Randomised Clinical Trial.

J Sleep Res · 2026 · PMC12931678 · PMID 40660750

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Daridorexant 50 mg also showed a trend to improved daytime functioning as assessed by the IDSIQ total score and the three IDSIQ domain scores, although the differences to placebo with both daridorexant doses in IDSIQ total score were not significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.